Nektar Therapeutics | NKTR - 销售和管理费用



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 15.95B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


销售和管理费用 更改 日
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
ALKERMES USD 264.59M 77.4M 2026-03
Alterity Therapeutics Limited AUD 1.45M 703.96K 2025-12
Amgen USD 1.58B 354M 2026-03
Baxter International USD 728M 33M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Biogen USD 554.3M 128.2M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Cara Therapeutics USD 2.19M 2.45M 2025-09
Cipla INR 13.25B 101.8M 2025-12
Dr.Reddys Laboratories INR 26.92B 482M 2025-12
Eisai JPY 111.72B 7.86B 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Esperion Therapeutics USD 39.42M 456K 2025-12
Exelixis USD 139.6M 16.58M 2026-03
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.12B 558M 2026-03
Grifols EUR 320.45M 12.65M 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Incyte USD 328.1M 62.31M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Merck USD 2.67B 180M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Novartis USD 3.14B 296M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Takeda JPY 282.78B 29.23B 2025-12
Teva Pharmaceutical Industries USD 1000M 120M 2026-03
Xencor USD 17.04M 70.74M 2025-12